Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.74 |
| ▸ | HRH2 | P25021 | 1/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094656 | 1.00 | HRH3 (0.74) | HRH3HRH2HRH1MAOBKDM4E | |
| Hydrochloric Acid SCHEMBL27711403 | 0.99 | HRH3 (0.73) | HRH3HRH2HRH1MAOBKDM4E | |
| Hydrochloric Acid SCHEMBL20511915 | 0.99 | HRH3 (0.73) | HRH3HRH2HRH1MAOBKDM4E | |
| Hydrochloric Acid SCHEMBL20511918 | 0.99 | HRH3 (0.73) | HRH3HRH2HRH1MAOBKDM4E | |
| Hydrochloric Acid SCHEMBL4595640 | 0.99 | HRH3 (0.73) | HRH3HRH2HRH1MAOBKDM4E | |
| Hydrochloric Acid SCHEMBL20509657 | 0.98 | HRH3 (0.71) | HRH3HRH2HRH1MAOBKDM4E | |
| Hydrochloric Acid SCHEMBL20509654 | 0.98 | HRH3 (0.71) | HRH3HRH2HRH1MAOBKDM4E | |
| Oxalic Acid SCHEMBL4595185 | 0.95 | HRH3 (0.71) | HRH3HRH2HRH1KDM4EALDH1A1 | |
| Oxalic Acid SCHEMBL20509707 | 0.95 | HRH3 (0.71) | HRH3HRH2HRH1KDM4EALDH1A1 | |
| Oxalic Acid SCHEMBL20509708 | 0.95 | HRH3 (0.71) | HRH3HRH2HRH1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600315-B1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET PHARMA (FR) | 2023-09-06 | — | — | EP | claimed |
| US-11179329-B2 | Therapeutical use of H3-ligands | BIOPROJET PHARMA (FR) | 2021-11-23 | — | — | US | claimed |
| US-11078183-B2 | Tetrahydrate of H3 ligand, its process of preparation and pharmaceutical compositions comprising the same | BIOPROJET (FR) | 2021-08-03 | — | — | US | claimed |
| EP-3601252-B1 | TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | BIOPROJET SOC CIV (FR) | 2021-02-17 | — | — | EP | claimed |
| US-20200093738-A1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET PHARMA (FR) | 2020-03-26 | — | — | US | claimed |
| EP-3600315-A1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET Pharma (FR) | 2020-02-05 | — | — | EP | claimed |
| EP-3601252-A1 | TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Bioprojet (FR) | 2020-02-05 | — | — | EP | claimed |
| WO-2018172432-A1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET PHARMA (FR) | 2018-09-27 | — | — | WO | claimed |
| WO-2018172344-A1 | TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | BIOPROJET (FR) | 2018-09-27 | — | — | WO | claimed |
| EP-3378477-A1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET Pharma (FR) | 2018-09-26 | — | — | EP | claimed |
| EP-3378858-A1 | TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Bioprojet (FR) | 2018-09-26 | — | — | EP | claimed |
| US-8076329-B2 | Histamine H3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2011-12-13 | — | — | US | claimed |
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2009-04-30 | — | — | US | claimed |
| US-12059416-B2 | Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof | BIOPROJET (FR) | 2024-08-13 | — | — | US | disclosed |
| EP-3600315-B1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | BIOPROJET PHARMA (FR) | 2023-09-06 | — | — | EP | disclosed |
| JP-2023001210-A | NOVEL THERAPEUTIC USES OF H3-LIGANDS | ビオプロジェ・ファルマ | 2023-01-04 | — | — | JP | disclosed |
| WO-2008009866-A2 | COMBINATION OF MODAFINIL AND AN ANTAGONIST OR INVERSE AGONIST OF THE H3 RECEPTOR | BIOPROJET (FR) | 2008-01-24 | — | — | WO | disclosed |
| EP-1874746-A2 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | BIOPROJET (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117609-A2 | PHENOXYPROPYLPIPERIDINES AND -PYRROLIDINES AND THEIR USE AS HISTAMINE H3 -RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-11-09 | — | — | WO | disclosed |
| EP-1717235-A2 | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands | BIOPROJET (FR) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179329-B2 | Therapeutical use of H3-ligands | HRH3, FCER2, FCGR2A | HRH3 1/4885HRH2 25/4885HRH1 30/4885 |
| US-12059416-B2 | Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof | HRH3, SLC6A2, HCRTR2 | HRH3 1/4885HRH2 35/4885HRH1 34/4885 |
| US-20090111808-A1 | NOVEL HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH1 | HRH3 1/4885HRH2 4/4885HRH1 3/4885 |
| US-20200093738-A1 | NEW THERAPEUTICAL USE OF H3-LIGANDS | HRH3, HNRNPH3, HRH4 | HRH3 1/4885HRH2 29/4885HRH1 28/4885 |
| US-11078183-B2 | Tetrahydrate of H3 ligand, its process of preparation and pharmaceutical compositions comprising the same | HRH3, HRH4, H1-3 | HRH3 1/4885HRH2 9/4885HRH1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.